Organon Operating Income Over Time
| OGN Stock | USD 8.21 0.11 1.36% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Organon Performance and Organon Correlation. Will Pharmaceuticals sector continue expanding? Could Organon diversify its offerings? Factors like these will boost the valuation of Organon. Anticipated expansion of Organon directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Organon data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.56) | Dividend Share 0.6 | Earnings Share 1.91 | Revenue Per Share | Quarterly Revenue Growth 0.013 |
Investors evaluate Organon using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Organon's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Organon's market price to deviate significantly from intrinsic value.
It's important to distinguish between Organon's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Organon should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Organon's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Operating Income Analysis
Compare Organon and related stocks such as Phibro Animal Health, Aurinia Pharmaceuticals, and Nuvation Bio Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PAHC | 15.7 M | 49.3 M | 56.7 M | 63.8 M | 87.7 M | 85.7 M | 97.9 M | 98.9 M | 73.3 M | 69.2 M | 74.9 M | 79 M | 71.8 M | 53.3 M | 110.5 M | 127 M | 133.4 M |
| AUPH | (2.7 M) | (6.4 M) | (5.5 M) | (5.5 M) | (17.3 M) | (23.6 M) | (22.8 M) | (47.1 M) | (56.2 M) | (90.9 M) | (104.3 M) | (180.7 M) | (111.5 M) | (91.7 M) | (4.7 M) | (4.2 M) | (4.4 M) |
| NUVB | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (32.1 M) | (43.6 M) | (93.3 M) | (119.7 M) | (99.8 M) | (592.6 M) | (533.4 M) | (506.7 M) |
| AVDL | (9 M) | (9.6 M) | (3.5 M) | (50 M) | (93.9 M) | 71.4 M | (5 M) | 88.3 M | (104.9 M) | (24.1 M) | 5.8 M | (85.5 M) | (98.6 M) | (137.8 M) | (42.4 M) | (38.2 M) | (40.1 M) |
| TLRY | (98.5 K) | (98.5 K) | (45.3 K) | (45.3 K) | (2.7 M) | (836.2 K) | (1 M) | (9.6 M) | (138.9 M) | (104 M) | (159.6 M) | (769.5 M) | (1.8 B) | (238.1 M) | (3.1 B) | (2.8 B) | (2.7 B) |
| HRMY | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (145.9 M) | 17 M | 87.5 M | 120.2 M | 192 M | 190.8 M | 219.4 M | 230.4 M |
| MD | 9.1 M | 355.4 M | 389.5 M | 452.1 M | 513 M | 557.9 M | 571.7 M | 480.1 M | 445.8 M | 171.8 M | 98.1 M | 202.9 M | 172.7 M | 7.3 M | (68.7 M) | (79 M) | (75.1 M) |
| GRDN | 25.9 M | 25.9 M | 25.9 M | 25.9 M | 25.9 M | 25.9 M | 25.9 M | 25.9 M | 25.9 M | 34.1 M | 32.1 M | 30.1 M | 52 M | 40.9 M | (62.9 M) | (56.6 M) | (53.8 M) |
| SEM | 119.1 M | 310.7 M | 336.9 M | 301.4 M | 284.5 M | 274.8 M | 299.8 M | 355.9 M | 417.3 M | 471.9 M | 567.7 M | 713.8 M | 403.3 M | 554.9 M | 268.3 M | 308.6 M | 374 M |
| ALVO | (61.4 M) | (61.4 M) | (61.4 M) | (61.4 M) | (61.4 M) | (61.4 M) | (61.4 M) | (61.4 M) | (61.4 M) | (61.4 M) | (137.5 M) | (235.5 M) | (346.4 M) | (354.9 M) | 69.6 M | 62.7 M | 65.8 M |
Organon and related stocks such as Phibro Animal Health, Aurinia Pharmaceuticals, and Nuvation Bio Operating Income description
Operating Income is the amount of profit realized from Organon operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Organon Co is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Organon Co | OGN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 30 Hudson Street, |
| Exchange | New York Stock Exchange |
USD 8.21
Check out Organon Performance and Organon Correlation. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Organon technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.